ClinicalTrials.gg

Program

Phenytoin

Also written as “Phenytoin (Ascoli)”, “Dilantin Infatabs (Phenytoin)” and “Phenytoin: Study Drug”.

Its studies are mostly in Epilepsy · Seizures · Hepatitis C, led by 8 companies.

Furthest: phase 3, since Apr 20, 201010 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatris30 open or runningphase 1since Apr 20, 2010Apr 20, 2010none ahead
GlaxoSmithKline10 open or runningphase 1since Feb 20, 2008Feb 20, 2008none ahead
Janssen Infectious Diseases BVBA10 open or runningphase 1since Jul 4, 2012Jul 4, 2012none ahead
Johnson & Johnson10 open or runningphase 3since Sep 13, 2005Sep 13, 2005none ahead
Merck10 open or runningphase 1since Mar 25, 2025Mar 25, 2025none ahead
Novartis11 open or runningphase 1since Aug 18, 2026Aug 18, 2026none ahead
Pfizer10 open or runningphase 1since Jun 14, 2024Jun 14, 2024none ahead
Zydus Lifesciences10 open or runningphase 1since Jun 23, 2021Jun 23, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 13, 2005First study: phase 3 study in EpilepsyNew to Johnson & JohnsonJohnson & Johnson · NCT00210782 · 262 enrolled
  2. Feb 20, 2008GlaxoSmithKline's first study: phase 1 study in EpilepsyNew to GlaxoSmithKlineGlaxoSmithKline · NCT00627575 · 119 enrolled · United States
  3. Apr 20, 2010Viatris's first studies: 2 phase 1 studies in HealthyNew to ViatrisViatris · NCT01122940, NCT01122953
  4. May 12, 2011Phase 1 study in SeizuresViatris · NCT01355068 · 26 enrolled · Singapore
  5. Jul 4, 2012Janssen Infectious Diseases BVBA's first study: phase 1 study in Hepatitis CNew to Janssen Infectious Diseases BVBAJanssen Infectious Diseases BVBA · NCT01635829 · 24 enrolled · Netherlands
  6. Jun 23, 2021Zydus Lifesciences's first study: phase 1 study in HealthyNew to Zydus LifesciencesZydus Lifesciences · NCT04981704 · 74 enrolled · United States
  7. Jun 14, 2024Pfizer's first study: phase 1 study in EpilepsyNew to PfizerPfizer · NCT06466473 · 35 enrolled · United States
  8. Mar 25, 2025Merck's first study: phase 1 study in HealthyNew to MerckMerck · NCT06903715 · 14 enrolled · United States
  9. Aug 18, 2026Novartis's first study: phase 1 study in Healthy ParticipantsNew to NovartisNovartis · NCT07783503 · 30 planned · United Kingdom

Ahead

  1. Nov 13, 2026Primary completion: phase 1 study in Healthy ParticipantsNovartis · NCT07783503

TargetBeta

“Sodium channel alpha subunit blocker; Sodium channel alpha subunit blocker”ChEMBL 37, by rule

Other programs on the same 10 targets

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
rufinamideruleEisaiphase 37

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07783503Healthy Participants · United Kingdom1RecruitingNovartisNov 13, 202630
NCT06903715Healthy · United States1CompletedMerckMay 8, 202514
NCT06466473Epilepsy · United States1CompletedPfizerOct 4, 202435
NCT04981704Healthy · United States1CompletedZydus LifesciencesJun 30, 202174
NCT01635829Hepatitis C · Netherlands1CompletedJanssen Infectious Diseases BVBAAug 201224
NCT01355068Seizures · Singapore1CompletedViatrisJun 201126
NCT01122953Healthy · Mexico1CompletedViatrisJun 201034
NCT01122940Healthy · Mexico1CompletedViatrisAug 201032
NCT00627575Epilepsy · United States1CompletedGlaxoSmithKlineSep 12, 2008119
NCT00210782Epilepsy3CompletedJohnson & Johnson262

How it is read

Names in the registry

  • “Phenytoin”, 5 entries
  • “Phenytoin (Ascoli)”, 1 entry
  • “Dilantin Infatabs (Phenytoin)”, 1 entry
  • “Phenytoin: Study Drug”, 1 entry
  • “phenytoin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.